Friday, February 24, 2012

Synthetic Biology: Emerging Global Markets

Synthetic Biology: Emerging Global Markets


NEW YORK, Dec. 19, 2011  /PRNewswire/ --

Reportlinker.com announces that a new market research report is available in its catalogue:

Synthetic Biology: Emerging Global Markets

http://www.reportlinker.com/p0128136/Synthetic-Biology-Emerging-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genetically_Modified_Organism,_GMO

REPORT SCOPE

INTRODUCTION

STUDY GOAL AND OBJECTIVES

BCC's goal for this study is to determine the specific applications and forecast global market demand for synthetic biology products over a 5-year period from 2011 to 2016. Our particular interest is to characterize and quantify the synthetic biology products market potential by product type and end use market segments. We also analyze the synthetic biology industry structure, competitors, and intellectual property landscape.

Synthetic biology markets reviewed in this report include enabling products, biologic components, integrated systems, and enabled products.

Our key objective is to present a comprehensive analysis of the emerging synthetic biology industry, with an emphasis on products and technologies that are commercially important in the 2011-to-2016 time period. Market segments with rapid growth rates are highlighted, as well as those segments with large market potential. This analysis provides a quantitative basis and market context for companies to make strategic choices about participation in the synthetic biology industry.

The study will be particularly useful to companies supplying synthetic genes, oligonucleotides, DNA sequencing instruments, cell culture media, biofuels, specialty chemicals, pharmaceuticals, vaccines, microfluidics, and life sciences tools.

REASONS FOR DOING THE STUDY

Synthetic biology is a rapidly emerging biotechnology discipline with a wide range of applications. Despite its emerging status, synthetic biology provides a significant number of near-term commercial opportunities, and the list of new products and applications is continuously growing. These applications include specialty chemicals, enzymes, synthetic genes and other DNA parts, pharmaceuticals, biofuels, and chassis microorganisms.

It is important for companies in industries affected by the developments in synthetic biology to sort through the many potential applications to identify near-term commercial opportunities for product development focus. This report allows companies to prioritize product opportunities, establishing a solid framework for strategic planning.

Synthetic biology encompasses a wide range of industries including life science tools, biotechnology, pharmaceuticals, diagnostics, energy, and chemicals. Because of its wide scope, synthetic biology plays an important role in the future of the industrial economy.

[caption id="attachment_81" align="aligncenter" width="400"]Synthetic Biology: Emerging Global Markets Synthetic Biology: Emerging Global Markets[/caption]

Ongoing advances in enabling technologies such as DNA synthesis and sequencing, specialty media, and bioinformatics, as well as a need for renewable feedstocks, are driving the growth of synthetic biology. Rapid developments in these multidisciplinary fields promise to advance the synthetic biology industry and create unique market opportunities. This report analyzes these trends and their impact on the future markets for synthetic biology products.

Based on these market and technology dynamics, it is especially timely to examine the current and future synthetic biology markets.

INTENDED AUDIENCE

We have compiled a study of existing and future synthetic biology products and technologies that will be commercially important in the main end user segments of life science research, pharmaceuticals, diagnostics, energy, chemicals, and agriculture.

We present markets by end use segment (R&D, diagnostics/pharmaceuticals, energy, chemicals, and agriculture) and by product type (enabling products, biologic components, integrated systems, and enabled products). Key market segments are covered, including synthetic genes, chassis organisms, biofuels, specialty chemicals, and pharmaceuticals.

We analyze synthetic biology technologies, growth driving forces, market applications, industry structure and competitive dynamics, companies and industry alliances, future market potential, and product sales forecasts for the period 2011 through 2016. We project the future use of synthetic biology products in the main end user segments and by product type.

This report will be of particular interest to pharmaceuticals, chemicals, enzymes, energy, agricultural, biotechnology, and bionanobiotechnology companies, as well as suppliers of genomics tools, DNA synthesis, and DNA sequencing products. It will also be of high interest to professionals within governments and regulatory agencies to understand the scope and pace of synthetic biology technologies as they reach the market.

SCOPE AND FORMAT

The study's scope includes core synthetic biology products (synthetic genes, other DNA parts, chassis organisms, synthetic cells), enabling technologies (DNA sequencing, oligonucleotides, specialty media, bioinformatics), and enabled technologies (biofuels, specialty chemicals, diagnostics, pharmaceuticals, agriculture) that are already commercial or forecast to be commercialized within the next 5 years.

We analyze key synthetic biology technologies and products to determine present and future market status, and forecast growth from 2011 through 2016. We also discuss strategic alliances, industry structures, competitive dynamics, patent strategy, and market driving forces.

BCC examines the synthetic biology industry by market segment, including suppliers of synthetic genes, enzymes, pharmaceutical companies, biofuels, and specialty chemicals. The role of key strategic alliances from 2009 through 2011 is discussed. Emerging markets including synthetic genes, synthetic biology-enabled drugs and vaccines, and chassis organisms are analyzed, as well as metabolically-engineered factories for producing synthetic fuels and specialty chemicals. The main companies in these fields are highlighted.

METHODOLOGY

BCC surveys key users and producers in each of the end user market segments and technology fields that will be commercially important during the next 5 years. Discussions with industry thought leaders, as well as secondary market research was performed.

Based on our analysis, we project the future applications of synthetic biology technologies in the major end user market segments and by technology type, and forecast sales revenues for 2011 through 2016.

INFORMATIION SOURCES

BCC surveyed leading synthetic biology, biotechnology, pharmaceutical, chemical, and energy companies to obtain data for this study. Included were life science research tools, drug, biotechnology, DNA synthesis and sequencing, and microfluidics firms, as well as leading life science research institutions. We also obtained inputs from leading academic and industry thought leaders. Data from secondary sources included industry, trade, and government publications.

Table of Contents

CHAPTER ONE: INTRODUCTION 1

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

INTENDED AUDIENCE 2

SCOPE AND FORMAT 3

METHODOLOGY 3

INFORMATION SOURCES 3

RELATED BCC REPORTS 4

ANALYST CREDENTIALS 4

BCC ON-LINE SERVICES 4

DISCLAIMER 4

DISCLAIMER (CONTINUED) 5

CHAPTER TWO: SUMMARY 6

SUMMARY TABLE GLOBAL VALUE OF SYNTHETIC BIOLOGY

MARKET, BY PRODUCT TYPE, THROUGH 2016 ($ MILLIONS) 6

SUMMARY FIGURE GLOBAL VALUE OF SYNTHETIC BIOLOGY

MARKET, BY PRODUCT TYPE, 2010-2016 ($ MILLIONS) 7

SUMMARY (CONTINUED) 8

CHAPTER THREE: OVERVIEW 9

SYNTHETIC BIOLOGY TECHNOLOGIES COVERED IN THIS

REPORT 9

TABLE 1 SCOPE OF THIS REPORT 9

FIGURE 1 SYNTHETIC BIOLOGY VALUE-ADDED CHAIN 10

WHAT IS SYNTHETIC BIOLOGY? 10

DEVELOPMENT STAGE OF SYNTHETIC BIOLOGY 11

FIGURE 2 FROM THE NATURAL TO THE ARTIFICIAL 12

FORCES DRIVING SYNTHETIC BIOLOGY MARKET GROWTH 13

TABLE 2 FORCES DRIVING THE GROWTH OF SYNTHETIC

BIOLOGY 13

GLOBAL MARKET POTENTIAL FOR SYNTHETIC BIOLOGY

PRODUCTS 14

TABLE 3 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET, BY

END USER INDUSTRY, THROUGH 2016 ($ MILLIONS) 15

LIFE CYCLE STATUS OF PRODUCTS AND TECHNOLOGIES 15

TABLE 4 SYNTHETIC BIOLOGY PRODUCTS AND TECHNOLOGY

LIFE CYCLE STAGE 16

THE SYNTHETIC BIOLOGY INDUSTRY 17

TABLE 5 SYNTHETIC BIOLOGY COMPETITORS BY MARKET

FOCUS 17

CHAPTER FOUR: SYNTHETIC BIOLOGY TECHNOLOGIES 18

INTRODUCTION 18

SYNTHETIC BIOLOGY DEFINED 18

TABLE 6 SYNTHETIC BIOLOGY DEFINITIONS 18

HISTORY OF SYNTHETIC BIOLOGY 19

TABLE 7 SYNTHETIC BIOLOGY HISTORY 19

TABLE 7 (CONTINUED) 20

History of Synthetic Biology (Continued) 21

PARADIGM SHIFT IN BIOLOGY 22

TABLE 8 PARADIGM SHIFT CAUSED BY SYNTHETIC BIOLOGY 22

TABLE 9 GENETIC ENGINEERING AND SYNTHETIC BIOLOGY

COMPARISON 23

Paradigm Shift In Biology (Continued) 24

FIGURE 3 SCALE OF SYNTHETIC BIOLOGY (BASE PAIRS) 25

SYNTHETIC BIOLOGY TECHNOLOGY OVERVIEW 26

TABLE 10 SYNTHETIC BIOLOGY APPLICATIONS BY TECHNOLOGY 26

ENABLING TECHNOLOGIES 27

TABLE 11 IMPORTANCE OF ENABLING TECHNOLOGIES 27

DNA SYNTHESIS AND SEQUENCING COST TRENDS 28

TABLE 12 COSTS TO SEQUENCE AND SYNTHESIZE A HUMAN

GENOME, 2001-2018 28

DNA SYNTHESIS TECHNOLOGIES 29

FIGURE 4 SCHEMATIC OF GENE SYNTHESIS TECHNOLOGIES 29

DNA Synthesis Technologies (Continued) 30

TABLE 13 COMPARISON OF GENE SYNTHESIS TECHNOLOGIES 31

PCR-based Approaches 31

Solid-phase Approaches 32

MICROFLUIDICS TECHNOLOGIES 33

TABLE 14 IMPORTANCE OF MICROFLUIDICS TECHNOLOGIES IN

SYNTHETIC BIOLOGY 33

DNA Microarrays – Oligos Synthesis 33

TABLE 15 MICROARRAY TYPES 34

TABLE 16 DNA MICROARRAY PLATFORM FEATURES 34

TABLE 17 DNA MICROARRAY PLATFORM COMPARISON FOR

MAJOR MANUFACTURERS 35

TABLE 17 (CONTINUED) 36

DNA Microarrays – … (Continued) 37

FIGURE 5 MICROARRAYS IN GENE SYNTHESIS 38

DNA SEQUENCING TECHNOLOGIES 39

TABLE 18 WORKFLOW COMPARISON OF SELECTED NEXTGENERATION

DNA SEQUENCING PLATFORMS 39

TABLE 19 BIOCHIP CONTENT IN NEXT-GENERATION

SEQUENCING MACHINES 40

DNA Sequencing Technologies (Continued) 41

BIOINFORMATICS TECHNOLOGIES 42

TABLE 20 SYNTHETIC BIOLOGY BIOINFORMATICS

TECHNOLOGIES 43

BIOLOGICAL COMPONENTS AND INTEGRATED SYSTEMS

TECHNOLOGIES 43

TABLE 21 NUCLEIC ACIDS, GENES, AND GENOMES 44

SYNTHETIC GENES 44

TABLE 22 SYNTHETIC GENES AS A MOLECULAR BIOLOGY TOOL 45

TABLE 23 SYNTHETIC GENES VERSUS PCR CLONING 46

Synthetic Genes (Continued) 47

BIOBRICK PARTS 48

TABLE 24 BIOBRICK PARTS 48

Biobrick Parts (Continued) 49

FIGURE 6 ROLE OF PROMOTERS AND REPORTERS IN

SYNTHETIC BIOLOGY SYSTEMS 50

MINIMAL GENOMES AND CHASSIS ORGANISMS 51

TABLE 25 ATTRIBUTES OF A MINIMAL GENOME 51

Case Study: Minimal E coli Genome 52

Role of Directed Evolution in Designing Biologic Parts 53

ENABLED TECHNOLOGIES 53

TABLE 26 ENABLED TECHNOLOGIES: EXISTING AND NEAR

TERM APPLICATIONS 54

PATHWAY ENGINEERING 54

FIGURE 7 HOW SYNTHETIC BIOLOGY CREATES ENABLED

PRODUCTS 55

TABLE 27 METABOLIC ENGINEERING FOR ARTEMISINIC ACID 56

SYNTHETIC MICROBIAL CONSORTIA 57

TABLE 28 APPLICATIONS FOR SYNTHETIC MICROBIAL

CONSORTIA 58

RESEARCH AND DEVELOPMENT APPLICATIONS 59

TABLE 29 RESEARCH & DEVELOPMENT APPLICATIONS FOR

SYNTHETIC BIOLOGY PRODUCTS 59

BIOFUELS TECHNOLOGIES 60

OVERVIEW 60

TABLE 30 ADVANCED BIOFUELS TYPES 61

FIRST AND SECOND GENERATION BIOFUELS

TECHNOLOGIES 62

TABLE 31 FIRST AND SECOND GENERATION BIOFUELS

COMPARED 62

CROP FEEDSTOCKS 63

TABLE 32 ENERGY BALANCE OF SELECTED FIRST GENERATION

BIOFUEL FEEDSTOCKS 64

CELLULOSIC FEEDSTOCKS 64

TABLE 33 APPROXIMATE COMPOSITION OF CELLULOSIC

BIOMASS (%) 64

TABLE 34 SYNTHETIC BIOLOGY STRATEGIES FOR CONVERTING

CELLULOSIC BIOMASS INTO ETHANOL 65

TABLE 35 BIOMASS ECONOMICS 66

ALGAE FEEDSTOCKS 66

TABLE 36 BIODIESEL YIELDS OF SELECTED CROPS 67

CARBON DIOXIDE FEEDSTOCKS 68

BIOFUEL END PRODUCTS 68

TABLE 37 EFFICIENCIES OF VARIOUS FUELS 69

Cellulosic Ethanol 69

FIGURE 8 CELLULOSIC ETHANOL PRODUCTION SCHEMATIC 70

Biodiesel 71

TABLE 38 IODINE NUMBER OF VARIOUS OILS 72

Other Biofuels 72

Role of Genetic Engineering and Synthetic Biology in

Biofuels 73

TABLE 39 CONTRIBUTION OF SYNTHETIC BIOLOGY TO BIOFUELS 73

Role of Genetic Engineering and … (Continued) 74

CHAPTER FIVE: SYNTHETIC BIOLOGY APPLICATIONS 75

INTRODUCTION 75

ENABLING TECHNOLOGIES APPLICATIONS 75

TABLE 40 SYNTHETIC BIOLOGY PRODUCTS IMPACTED BY

ENABLING TECHNOLOGIES 75

BIOLOGICAL COMPONENTS AND INTEGRATED SYSTEMS

APPLICATIONS 76

TABLE 41 BIOLOGICAL COMPONENTS AND INTEGRATED

SYSTEMS NEAR-TERM APPLICATIONS 76

SYNTHETIC GENE APPLICATIONS 77

TABLE 42 SYNTHETIC GENES NEAR-TERM APPLICATIONS 77

Synthetic Gene Applications (Continued) 78

BIOBRICK PARTS APPLICATIONS 79

Biobrick Parts Applications (Continued) 80

INTEGRATED SYSTEMS APPLICATIONS 81

TABLE 43 E COLI AS A CHASSIS ORGANISM 81

Integrated Systems Applications (Continued) 82

Synthetic Cells and Tissues 83

Cellular Factories 83

ENABLED PRODUCT APPLICATIONS 83

PHARMACEUTICALS 84

TABLE 44 SYNTHETIC BIOLOGY-ENABLED DRUG CLASSES 84

TABLE 45 DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS

FOR SYNTHETIC BIOLOGY PRODUCTS 85

TABLE 46 SYNTHETIC BIOLOGY-ENABLED PHARMACEUTICAL

APPLICATIONS 86

Pharmaceuticals (Continued) 87

DIAGNOSTICS 88

TABLE 47 SYNTHETIC BIOLOGY-ENABLED DIAGNOSTICS

APPLICATIONS 88

BIOFUELS 89

TABLE 48 SYNTHETIC BIOLOGY-ENABLED BIOFUELS

APPLICATIONS 89

TABLE 49 GROWTH STATUS OF SPECIALTY VERSUS DROP-IN

BIOFUELS, 2000-2020 90

CHEMICALS 90

TABLE 50 SYNTHETIC BIOLOGY-ENABLED CHEMICALS

APPLICATIONS 90

TABLE 50 (CONTINUED) 91

ENGINEERED PLANTS AND INSECTS 91

TABLE 51 SYNTHETIC BIOLOGY-ENABLED ENGINEERED PLANTS

AND INSECTS APPLICATIONS 92

PRODUCTION PROCESSES 92

TABLE 52 SYNTHETIC BIOLOGY-ENABLED PRODUCTION

PROCESSES APPLICATIONS 93

CHAPTER SIX: SYNTHETIC BIOLOGY INDUSTRY 94

INDUSTRIAL BIOTECHNOLOGY VALUE CHAIN 94

FIGURE 9 INDUSTRIAL BIOTECHNOLOGY VALUE CHAIN WITH

SYNTHETIC BIOLOGY LEVERAGE POINTS 95

INDUSTRY STRUCTURAL FORCES 96

TABLE 53 SYNTHETIC BIOLOGY INDUSTRY STRUCTURAL FORCES 96

INDUSTRY STRUCTURAL FORCES (CONTINUED) 97

PRODUCTS AND TECHNOLOGY LIFE CYCLE 98

TABLE 54 SYNTHETIC BIOLOGY PRODUCTS AND TECHNOLOGY

LIFE CYCLE STAGES 98

GENE SYNTHESIS INDUSTRY 99

GENE SYNTHESIS WORKFLOW 99

TABLE 55 GENE SYNTHESIS WORKFLOW 99

Gene Synthesis Workflow (Continued) 100

GENE SYNTHESIS COMPETITORS 101

TABLE 56 SYNTHETIC GENE COMPANY ESTIMATED 2010 MARKET

SHARES ($ MILLIONS/%) 102

Gene Synthesis Competitors (Continued) 103

TABLE 57 SYNTHETIC GENE KEY COMPETITOR STRATEGIES 104

GENE SYNTHESIS VALUE CHAIN 105

SYNTHETIC GENE MARKET SEGMENTS 106

Automated Standardized Segment 107

Value Added Segment 107

TABLE 58 GENE SYNTHESIS MARKET FACTORS OF

DIFFERENTIATION 108

BIOFUELS INDUSTRY 109

COMPETITIVE DIFFERENTIATION 109

FEEDSTOCKS 109

TABLE 59 BIOFUELS: FEEDSTOCKS, PRODUCTION AND

PRODUCTS 110

TABLE 60 BIOFUELS FEEDSTOCKS: RELATIVE SUPPLY VOLUME

AND COSTS 111

Sugars/Starches 111

Vegetable Oils 111

Biomasses 111

Algae 112

CO2 112

BIOFUEL COMPETITOR STRATEGIES 112

TABLE 61 SYNTHETIC BIOLOGY BIOFUELS COMPANY

STRATEGIES 113

TABLE 61 (CONTINUED) 114

Biofuel Competitor Strategies (Continued) 115

Biofuel Competitor Strategies (Continued) 116

Biofuel Competitor Strategies (Continued) 117

CHEMICALS INDUSTRY 118

TABLE 62 SYNTHETIC BIOLOGY-ENABLED CHEMICALS

APPLICATIONS 118

TABLE 63 VALUE-ADDED IN SELECTED END MARKETS 119

ENZYMES INDUSTRY 120

TABLE 64 ENZYME COMPANY KEY ALLIANCES 120

TABLE 64 (CONTINUED) 121

PHARMACEUTICALS INDUSTRY 122

TABLE 65 SYNTHETIC BIOLOGY-ENABLED DRUG STRATEGIES 122

TABLE 65 (CONTINUED) 123

ACQUISITIONS AND STRATEGIC ALLIANCES 124

TABLE 66 SYNTHETIC BIOLOGY INDUSTRY ACQUISITIONS, 2010–

2011 125

Acquisitions and Strategic Alliances (Continued) 126

Acquisitions and Strategic Alliances (Continued) 127

TABLE 67 STRATEGIC ALLIANCES, 2009–2011 128

TABLE 67 (CONTINUED) 129

TABLE 67 (CONTINUED) 130

TABLE 67 (CONTINUED) 131

Acquisitions and Strategic Alliances (Continued) 132

Acquisitions and Strategic Alliances (Continued) 133

Acquisitions and Strategic Alliances (Continued) 134

Acquisitions and Strategic Alliances (Continued) 135

Acquisitions and Strategic Alliances (Continued) 136

Acquisitions and Strategic Alliances (Continued) 137

Acquisitions and Strategic Alliances (Continued) 138

CHAPTER SEVEN: SYNTHETIC BIOLOGY MARKETS 139

INDUSTRY GROWTH DRIVING FORCES 139

TABLE 68 SYNTHETIC BIOLOGY GROWTH DRIVING FORCES 139

INDUSTRY GROWTH DRIVING FORCES (CONTINUED) 140

MACROECONOMIC FORECASTING ASSUMPTIONS 141

FIGURE 10 MARKET FORECAST SCENARIO TABLE 142

SYNTHETIC BIOLOGY MARKETS BY END USER INDUSTRY 143

TABLE 69 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET, BY

END USER INDUSTRY, THROUGH 2016 ($ MILLIONS) 143

R&D MARKET 144

TABLE 70 GLOBAL VALUE OF R&D MARKET, BY PRODUCT TYPE,

THROUGH 2016 ($ MILLIONS) 144

DIAGNOSTICS AND PHARMACEUTICALS MARKET 145

TABLE 71 GLOBAL VALUE OF DIAGNOSTICS/PHARMACEUTICALS

MARKET, BY PRODUCT TYPE, THROUGH 2016 ($ MILLIONS) 145

Diagnostics and Pharmaceuticals Market (Continued) 146

CHEMICALS MARKET 147

TABLE 72 GLOBAL VALUE OF CHEMICALS MARKET, BY PRODUCT

TYPE, THROUGH 2016 ($ MILLIONS) 148

ENERGY MARKET 148

TABLE 73 GLOBAL VALUE OF ENERGY MARKET, BY PRODUCT

TYPE, THROUGH 2016 ($ MILLIONS) 149

AGRICULTURE MARKET 149

TABLE 74 GLOBAL VALUE OF AGRICULTURE MARKET, BY

PRODUCT TYPE, THROUGH 2016 ($ MILLIONS) 150

SYNTHETIC BIOLOGY MARKETS BY PRODUCT TYPE 150

SUMMARY 150

TABLE 75 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET, BY

PRODUCT TYPE, THROUGH 2016 ($ MILLIONS) 151

ENABLING PRODUCTS MARKETS 152

TABLE 76 GLOBAL VALUE OF SYNTHETIC BIOLOGY ENABLING

PRODUCTS, BY TYPE, THROUGH 2016 ($ MILLIONS) 152

TABLE 77 GLOBAL VALUE OF SYNTHETIC BIOLOGY ENABLING

PRODUCTS, BY INDUSTRY, THROUGH 2016 ($ MILLIONS) 153

BIOLOGIC COMPONENTS MARKET 154

TABLE 78 GLOBAL VALUE OF BIOLOGIC COMPONENTS MARKET,

BY TYPE, THROUGH 2016 ($ MILLIONS) 155

Synthetic Gene Standardized Market Segment 155

Synthetic Gene Value-added Market Segment 155

TABLE 79 GLOBAL VALUE OF BIOLOGIC COMPONENTS MARKET,

BY INDUSTRY, THROUGH 2016 ($ MILLIONS) 156

Synthetic Gene Value-… (Continued) 157

INTEGRATED SYSTEMS MARKET 158

TABLE 80 BIOLOGICAL COMPONENTS AND INTEGRATED

SYSTEMS NEAR-TERM APPLICATIONS 158

TABLE 81 GLOBAL VALUE OF INTEGRATED SYSTEMS MARKET,

BY TYPE, THROUGH 2016 ($ MILLIONS) 158

Integrated Systems Market (Continued) 159

TABLE 82 GLOBAL VALUE OF INTEGRATED SYSTEMS MARKET,

BY INDUSTRY, THROUGH 2016 ($ MILLIONS) 160

ENABLED PRODUCTS MARKET 160

SOURCES OF COMPETITIVE ADVANTAGE 160

TABLE 83 BIODIESEL FUEL PERFORMANCE COMPARISON 161

TABLE 84 ARTEMISININ DRUG PRODUCTION COMPARISON 162

TABLE 85 GLOBAL VALUE OF SYNTHETIC BIOLOGY ENABLED

PRODUCTS MARKET, BY INDUSTRY, THROUGH 2016 ($

MILLIONS) 162

DIAGNOSTICS AND PHARMACEUTICALS MARKET 163

TABLE 86 GLOBAL VALUE OF ENABLED DIAGNOSTIC AND

PHARMACEUTICALS MARKET, BY INDUSTRY, THROUGH 2016 ($

MILLIONS) 164

TABLE 87 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED

DIAGNOSTICS MARKET, BY INDICATION, THROUGH 2016 ($

MILLIONS) 164

TABLE 88 GLOBAL VALUE OF ENABLED PHARMACEUTICALS

MARKET, BY DRUG CLASS, THROUGH 2016 ($ MILLIONS) 165

Diagnostics and Pharmaceuticals Market (Continued) 166

CHEMICALS MARKET 167

TABLE 89 GLOBAL VALUE OF ENABLED CHEMICALS MARKET, BY

PRODUCT TYPE, THROUGH 2016 ($ MILLIONS) 168

BIOFUELS MARKET 169

TABLE 90 ADVANCED BIOFUEL GROWTH DRIVING FACTORS 170

TABLE 91 PUBLIC AND PRIVATE FUNDING FOR SELECTED

BIOFUELS COMPANIES 171

TABLE 92 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED

BIOFUELS MARKET, BY FUEL TYPE, THROUGH 2016 ($

MILLIONS) 172

AGRICULTURE MARKET 173

TABLE 93 GLOBAL VALUE OF AGRICULTURE MARKET, BY

APPLICATION, THROUGH 2016 ($ MILLIONS) 173

ALL PRODUCTS BY GEOGRAPHY 174

TABLE 94 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET, BY

GEOGRAPHY, THROUGH 2016 ($ MILLIONS) 175

ENABLING PRODUCTS MARKET BY GEOGRAPHY 176

TABLE 95 GLOBAL VALUE OF ENABLING PRODUCTS MARKET, BY

GEOGRAPHY, THROUGH 2016 ($ MILLIONS) 176

CORE PRODUCTS BY GEOGRAPHY 176

TABLE 96 GLOBAL VALUE OF CORE PRODUCTS MARKET, BY

GEOGRAPHY, THROUGH 2016 ($ MILLIONS) 177

ENABLED PRODUCTS BY GEOGRAPHY 177

TABLE 97 GLOBAL VALUE OF ENABLED PRODUCTS MARKET, BY

GEOGRAPHY, THROUGH 2016($ MILLIONS) 178

Enabled Products by Geography (Continued) 179

CHAPTER EIGHT: PATENTS 180

INTRODUCTION 180

TABLE 98 SYNTHETIC BIOLOGY PATENT SCOPE 181

FOUNDATIONAL PATENTS 181

TABLE 99 SYNTHETIC BIOLOGY FOUNDATIONAL PATENTS 182

Enabled Products by Geography (Continued) 183

SYNTHETIC BIOLOGY INDUSTRY PATENT ANALYSIS 184

FIGURE 11 NUMBER OF PATENTS BY COMPANY 185

FIGURE 11 (CONTINUED) 186

FIGURE 12 PATENTS BY COMPANY AND SUBCLASS 187

FIGURE 12 (CONTINUED) 188

TABLE 100 PATENT DESCRIPTION BY COMPANY 189

TABLE 100 (CONTINUED) 190

PATENT STRATEGY OF SELECTED COMPANIES 191

METABOLIX 191

DUPONT 191

GENEART (LIFE TECHNOLOGIES) 192

FEBIT 192

BIOTICA 193

CHAPTER NINE: COMPANY PROFILES 194

AGRIVIDA 194

TABLE 101 AGRIVIDA TECHNICAL APPROACH 194

ALGENICS 195

ALGENOL BIOFUELS 196

ALLOPARTIS BIOTECHNOLOGIES, INC 196

ALLYLIX 197

AMBRX, INC 197

AMYRIS BIOTECHNOLOGIES, INC 198

TABLE 102 AMYRIS SPECIALTY CHEMICALS STRATEGY 199

TABLE 103 AMYRIS BIODIESEL ADVANTAGES 200

ATG BIOSYNTHETICS GMBH 201

BASF AG 202

BAYER AG 203

BIOAMBER INC 203

BIOBASIC INC 204

BIOCALDOL LTD 204

BIOCAT GMBH 204

BIONEER CORPORATION 205

BIONEXUS INC 206

BIOSEARCH TECHNOLOGIES, INC 206

BIO S&T, INC 207

BIOTICA TECHNOLOGY LTD 207

BIOTICA TECHNOLOGY LTD (CONTINUED) 208

TABLE 104 STRUCTURE-FUNCTION APPROACH FOR RAPAMYCIN 209

BLUE MARBLE ENERGY 210

BRISTOL MYERS SQUIBB 210

BRISTOL MYERS SQUIBB (CONTINUED) 211

BRITISH PETROLEUM 212

COBALT TECHNOLOGIES 213

CODEXIS, INC 214

DANISCO A/S 215

DNA20 216

DNA20 (CONTINUED) 217

DOW CHEMICAL COMPANY 218

DRATHS CORPORATION 218

DRATHS CORPORATION (CONTINUED) 219

EI DU PONT DE NEMOURS AND COMPANY 220

EI DU PONT DE NEMOURS …(CONTINUED) 221

DYADIC INTERNATIONAL 222

ENTELECHON GMBH 222

EPOCH LIFE SCIENCE, INC 223

EUROFINS MWG OPERON 224

EVOLVA SA 224

TABLE 105 EVOLVA'S GENETIC CHEMISTRY PLATFORM 225

TABLE 106 EVOLVA STRATEGIC ALLIANCES 226

TABLE 107 EVOLVA PRODUCT PIPELINE 226

EXXONMOBIL CORPORATION 227

FEBIT HOLDING GMBH 228

FLUXOME A/S 229

GENEMED SYNTHESIS INC 229

GENEWORKS PTY LTD 230

GENEORACLE, INC 230

GENOMATICA 230

GENSCRIPT USA INC 231

GEVO, INC 232

GINKGO BIOWORKS 233

GLYCOS BIOTECHNOLOGIES, INC 234

GOODYEAR TIRE & RUBBER 234

GREEN BIOLOGICS LTD 235

ILLUMINA, INC 235

ILLUMINA, INC (CONTINUED) 236

INGENZA LTD 237

INTEGRATED DNA TECHNOLOGIES, INC 238

INSTITUTE FOR ONEWORLD HEALTH 238

IOGEN CORPORATION 239

INTREXON CORPORATION 239

TABLE 108 INTREXON ULTRAVECTOR PARTS INVENTORY

EXAMPLES 240

JOULE UNLIMITED 241

KIVERDI, INC 242

LC SCIENCES 242

LIFE TECHNOLOGIES, INC 243

LIFE TECHNOLOGIES, INC (CONTINUED) 244

LS9, INC 245

LUMINEX 246

MASCOMA 247

MERCK & CO 248

METABOLIX INC 248

TABLE 109 MIREL'S COMPETITORS IN BIOPLASTICS 249

METRIGEN, INC 250

MODULAR GENETICS 250

MORPHOSYS AG 250

MYRIANT TECHNOLOGIES 251

NEW ENGLAND BIOLABS 252

NOVACTA BIOSYSTEMS LTD 253

NOVOZYMES A/S 253

OMEGA BIO-TEK, INC 254

OPX BIOTECHNOLOGIES, INC 255

ORIGENE TECHNOLOGIES 256

OXITEC LTD 256

PACIFIC BIOSCIENCES 257

PFIZER 258

PROTERRO INC 259

PROTOLIFE SRL 260

QTEROS, INC 260

RENNOVIA, INC 261

ROCHE LIFE SCIENCES 261

ROYAL DSM NV 262

SANGAMO BIOSCIENCES, INC 263

TABLE 110 SANGAMO STRATEGIC ALLIANCES 264

SANGAMO BIOSCIENCES, INC (CONTINUED) 265

SANOFI AVENTIS 266

SAPPHIRE ENERGY 267

SCARAB GENOMICS, LLC 267

SHANGHAI GENERAY BIOTECH CO, LTD 268

SHANGHAI SHINEGENE MOLECULAR BIO-TECHNOLOGIES,

INC 268

SOLAZYME, INC 269

TABLE 111 SOLAZYME STRATEGIC ALLIANCES 270

SUTRO BIOPHARMA, INC 271

SWITCHGEAR GENOMICS 271

SYNPROMICS LTD 272

SYNTHETIC GENOMICS INC 272

SYNTHETIC GENOMICS INC (CONTINUED) 273

TABLE 112 SYNTHETIC GENOMICS STRATEGIC ALLIANCES 274

THERMO FISHER SCIENTIFIC 275

VERDEZYNE, INC 275

VERENIUM CORPORATION 276

VERENIUM CORPORATION (CONTINUED) 277

VIRAL GENETICS INC 278

ZIOPHARM ONCOLOGY, INC 278

ZIOPHARM ONCOLOGY, INC (CONTINUED) 279

To order this report: Genetically Modified Organism, GMO IndustrySynthetic Biology: Emerging Global Markets

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

News Release Source : http://www.prnewswire.com/news-releases/synthetic-biology-emerging-global-markets-135846668.html

The Governance of Synthetic Biology

The Governance of Synthetic Biology


Are We Making Progress?

WASHINGTON, Feb. 8, 2012 /PRNewswire-USNewswire/ -- The Synthetic Biology Project at the Woodrow Wilson Center is launching a new web-based Synthetic Biology Scorecard, designed to track federal and non-federal efforts to improve the governance of synthetic biology research and development so risks are minimized and broad social and economic benefits can be realized.

The Scorecard, unveiled today, monitors the progress made toward implementing the recommendations in New Directions: The Ethics of Synthetic Biology and Emerging Technologies, a December 2010 report from the Presidential Commission for the Study of Bioethical Issues. The report contains 18 recommendations covering a range of topics from risk assessment to ethics education and public engagement.

[caption id="attachment_83" align="aligncenter" width="300"]The Governance of Synthetic Biology The Governance of Synthetic Biology[/caption]

More than a year has passed since the release of the Commission's report. What progress has been made? The Scorecard seeks to answer that question: In addition to tracking the progress of various federal and non-federal initiatives, the website encourages broad participation in achieving the goals set forth by the Commission and invites public comment on the recommendations and implementation efforts.

"The Commission's report was a landmark document and lays out a framework with broad applicability to many emerging technologies, but, like many reports of this type, no mechanisms were put in place to track progress," David Rejeski, director of the Synthetic Biology Project, said. "Our goal is ensure that this report -- and others like it – can drive change."

Valerie Bonham, executive director of the Commission, said, "Throughout the Commission's deliberations and in the report, the members emphasized the need for transparency, dialogue, and accountability around synthetic biology."

President Obama requested the Commission's report almost two years ago in response to important advancements in the field of synthetic biology. On May 20, 2010, scientists at the J.C. Venter Institute unveiled a bacterial cell controlled by a synthetic genome. That same day, the president asked the Commission to undertake "a study of the implications of this scientific milestone . . . [and] consider the potential medical, environmental, security, and other benefits of this field of research, as well as any potential health, security, or other risks."

Following the launch of the Scorecard, the Synthetic Biology Project will update the website to reflect new initiatives and publish a bi-annual summary of federal and non-federal activities that fulfill the recommendations. Additions to the Scorecard are welcome and encouraged.

The Synthetic Biology Scorecard can be found here: http://www.synbioproject.org/scorecard/

The Woodrow Wilson International Center for Scholars

The Woodrow Wilson International Center for Scholars is the national, living memorial honoring President Woodrow Wilson. The Wilson Center provides a strictly nonpartisan space for the worlds of policymaking and scholarship to interact. By conducting relevant and timely research and promoting dialogue from all perspectives, it works to address the critical current and emerging challenges confronting the United States and the world. Created by an Act of Congress in 1968, The Wilson Center is a non-partisan institution headquartered in Washington, D.C. and supported by both public and private funds.

SOURCE Woodrow Wilson Center

News Release Source :  The Governance of Synthetic Biology

Thursday, February 2, 2012

Synthetic Biology : The Future of Chemical Manufacturers

Synthetic Biology - The Future of Chemical Manufacturers


By Chris Jenkinson


Advancing technology and new uses for old substances may substantially change the future for chemical manufacturers. Synthetic biology as a factor of applied biotechnology will produce some innovative new ways for manufacturing facilities to produce the vast amount of chemicals required by various industries.

[caption id="attachment_86" align="aligncenter" width="450"]Synthetic Biology  - The Future of Chemical Manufacturers Synthetic Biology - The Future of Chemical Manufacturers[/caption]

Chemical Manufacturing in the Past

In the past, plant matter supplied the raw material to produce chemicals. It was not until petroleum came along that a wider variety of plastics and other substances were invented. Indeed, this was viewed as one of the greatest advances in the 20th century.

Now, due to advances in genetic engineering, new possibilities exist for manufacture of chemicals through the use of synthetic biology.

How It Works

The aim of synthetic biologists is to create an organism from scratch. They are using an approach similar to that of other types of engineering in the design and construction of systems that will support this new technology.

This new focus is referred to as systems biology. It is the key to learning how to design and engineer parts, devices and systems of a biological nature from standardised elements that are readily available (referred to as biobricks or bioparts).

Another sector of the field is experimenting with algae to produce oils that can be refined into diesel fuel. Algae cells are fed biomass made from natural substances such as sugar cane in the dark, bio-engineering that allows the algae to make oil without going through the process of photosynthesis. Further into the future, the hope is that the resultant oil can function as a triglyceride oil for the manufacture of other chemical products.

Synthetic biology will make great strides in improving chemical manufacturing processes when it can develop fermentation that results in the creation of industrial monomers. The value of these monomers will be in their lower cost and the ability to manufacture in smaller volume batches - making them a more valuable commodity than petrochemicals. As well, synthetic biology will allow the substances to be manipulated to provide a high degree of specialisation to achieve specific performance goals and product features. The future could become reality in this respect in just two years.

There is no doubt synthetic biology still has a long way to go toward becoming the new replacement for non-renewable sources used by chemical manufacturers. However, the possibilities are exciting, and this modern field offers hope for the creation of cheaper, sustainable materials.

Witton have been chemical manufacturers for more than 50 years, working with some of the largest adhesive, electronic, paint, sealant, petrochemical, and pharmaceutical companies worldwide.

Article Source: http://EzineArticles.com/?expert=Chris_Jenkinson
http://EzineArticles.com/?Synthetic-Biology---The-Future-of-Chemical-Manufacturers&id=2602412